Despite these limitations, the findings of the present study suggest that DUOX2 can be a novel biomarker for predicting non-CR after CCRT in patients with rectal cancer, highlighting the importance of the tumor microenvironment with respect to treatment responsiveness. Here, DUOX2 is linked to neoplasm.